John Varga

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch et al. · Journal of the American College of Cardiology · 2009 · 2.4K citations

Medicine, Cardiology, Internal Medicine +16

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1.1K citations

Medicine, Pharmacology, Pharmacotherapy +11

Transforming growth factor <i>β</i> (TGF<i>β</i>) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts

John Varga, J. Rosenbloom, Sergio A. Jiménez · Biochemical Journal · 1987 · 590 citations · Full text

Life Sciences, Molecular Biology, Gene Expression +12

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 464 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15